We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
THE EFFECT OF TROGLITAZONE ON C-REACTIVE PROTEIN IN INDIVIDUALS WITH PREDIABETES: DATA FROM THE DIABETES PREVENTION PROGRAM.
- Authors
Mokthar, Khalid; Hamadain, Elgenaid
- Abstract
Background Inflammation has been clearly recognized as a factor in the development and progression of multiple cardiovascular (CVD) diseases especially atherosclerosis and coronary heart diseases (CHD). The importance of Creactive protein (CRP) levels in the prediction of future cardiovascular evens has been underscored in multiple studies. Limited studies investigated the effect of troglitazone on inflammatory markers including CRP levels in individuals with diabetes mellitus (DM), very few analyzed this effect on individuals with prediabetes. The Diabetes Prevention Program (DPP) is a large randomized trial which evaluated the effect of different interventions including metformin and intensive lifestyle modifications (ILS) compared to placebo on the prevention of DM. In this study we evaluated the effect of troglitazone on CRP levels in a subgroup of the DPP population. Materials and Methods: A subgroup of a total of 3,171 subjects from the original DPP study population was selected for this analysis. The effect of troglitazone on inflammatory markers was measured by analyzing its effects on CRP levels at baseline and at 12 months and compared it to the other three interventions (ILS, metformin, and placebo). Results: Overall, the median percentage change in CRP at 1 year from baseline was -20.00 percent in the troglitazone arm (p <0.001 for all between group analysis: troglitazone vs. lifestyle, troglitazone vs. metformin, & troglitazone vs. placebo). Due to the differences in CRP levels with sex where women usually report higher baseline CRP values than men, the effect of the interventions was also reported by sex. In women, the median percent change in CRP at 1 year from baseline was -27.08 percent in the troglitazone arm (troglitazone vs. lifestyle: P = 0.854; troglitazone vs. placebo: P <0.001; and troglitazone vs. metformin: P=0.001). In men, troglitazone reported a median percentage change of -4.64 percent in CRP levels (troglitazone vs. lifestyle: P = 0.012; troglitazone vs. placebo: P = 0.012; and troglitazone vs. metformin: P = 0.33). Conclusion This analysis showed a significant decrease in CRP levels due to troglitazone treatment for 1 year, the reduction was significantly greater that what is produced by metformin.
- Subjects
TROGLITAZONE; C-reactive protein; CARDIOVASCULAR diseases; ATHEROSCLEROSIS; DIABETES
- Publication
Journal of the Mississippi Academy of Sciences, 2018, Vol 62, Issue 2 Supplement, p275
- ISSN
0076-9436
- Publication type
Article